Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies.

Front Oncol · 2020 · PMC7649373 · PMID 33194749

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Importantly, an exploratory analysis of a phase I clinical trial ( NCT02861300 ) showed a trend of better response to combination therapy of CB-839 plus capecitabine (prodrug of 5-fluorouracil) in PIK3CA-mutant CRC patients as compared to PIK3CA-WT cohort ( 148 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.